Marketing: Page 64
-
ICER questions cost effectiveness of multiple myeloma therapies
Some of the newer multiple myeloma drugs, including Amgen's Kyprolis, have cost effectiveness ratios above the accepted threshold for the Institute for Clinical and Economic Review.
By Nicole Gray • April 13, 2016 -
PledPharma takes on chemo-induced neuropathy with an eye to US market
As many as half of all cancer patients experience peripheral neuropathy brought on by chemo regimens.
By Nicole Gray • April 13, 2016 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
With Sanofi gone, Mannkind tries to reinvigorate Afrezza marketing
The company is essentially re-launching the inhaled insulin product, adding a new chief commercial officer, ad agency and specialist focus.
By Nicole Gray • April 12, 2016 -
Life after Shkreli: KaloBios promises affordable drugs, no 'price gouging'
Under former CEO Martin Shkreli, the company had planned to acquire rights to a rare tropical disease drug and drastically increase its price.
By Ned Pagliarulo • April 11, 2016 -
Philippines launches world's first public immunization program against dengue
The program will be administering Sanofi's dengvaxia, the only approved vaccine for dengue.
By Nicole Gray • April 6, 2016 -
New data: Pharma magazine ad spending surpasses $1.5 billion in 2015
The pharma industry outspent all other major consumer categories in total magazine ad spend.
By Nicole Gray • April 6, 2016 -
FDA
FDA chastises Shionogi for misleading copay voucher
At issue is the omission of important risk information in a copay assistance voucher for the lice treatment Ulesfia.
By Nicole Gray • April 6, 2016 -
BIO Spring 2016: Immunovia's quest to make early-stage pancreatic diagnosis a clinical reality
The Swedish company is working to build an evidence base for its serum-based cancer diagnostic in the U.S. market.
By Nicole Gray • April 6, 2016 -
Remicade copy clears FDA, becomes second biosim to win approval in U.S.
The biosimilar version of J&J's blockbuster inflammatory drug will be co-marketed by the Korean drugmaker Celltrion and Pfizer as Inflectra.
By Ned Pagliarulo • April 5, 2016 -
Analysis shows pharma companies aggressively increased prices on widely used drugs
Four of the top 10 drugs more than doubled in price between 2011 and 2014, according to the report.
By Nicole Gray • April 5, 2016 -
Report: Valeant cuts sales force for female libido drug
Addyi has been a sales disappointment since its launch in October.
By Ned Pagliarulo • April 4, 2016 -
Samsung Bioepis' biosim of Remicade clears regulatory hurdle in EU
Samsung's version would be the second copy of Remicade in the EU, if approved. South Korea-based Celltrion previously won approval for its drug Remsima.
By Ned Pagliarulo • April 1, 2016 -
GSK won't file drug patents in low-income countries
Additionally, the drugmaker will offer 10-year licenses for generic versions of its medicines in lower middle income countries.
By Ned Pagliarulo • March 31, 2016 -
Could long-term "mortgages" help patients fund short-term curative treatments?
A recent article proposed long-term installment loans as a potential solution for increasing access to pricey, but extremely effective drugs like Harvoni.
By Nicole Gray • March 30, 2016 -
Xenoport sells US rights to psoriasis drug to Dr. Reddy's
CA-based Xenoport has struggled with mixed clinical trial results for its psoriasis candidate and financial woes that led to layoffs.
By Nicole Gray • March 30, 2016 -
Denmark-based Lundbeck emerges as top-ranked company in survey of US patient groups
It fared particularly well in measures of patient-centricity and transparency.
By Nicole Gray • March 30, 2016 -
In reversal, FDA denies cognitive dysfunction label expansion for Brintellix
An advisory committee had previously recommended approval for the new indication in February.
By Nicole Gray • March 30, 2016 -
US gov demands more information from Novartis on purported kickbacks
The drugmaker is accused of treating doctors to expensive meals in return for prescribing Novartis' drugs.
By Nicole Gray • March 28, 2016 -
Spending on Vertex's Kalydeco consumed 86% of Scottish rare disease fund's budget
The special government fund reportedly spent £18.6 million on the cystic fibrosis drug between 2013 and 2014.
By Ned Pagliarulo • March 28, 2016 -
Valeant doubled price of physician-assisted suicide drug
The drugmaker increased the price of the drug shortly after acquiring it, and one month after lawmakers in California proposed aid-in-dying legislation.
By Nicole Gray • March 24, 2016 -
Brexit could complicate marketing status of drugs, new licenses
The European pharma industry has strongly opposed a U.K. exit from the E.U. The U.K. votes in a June 23 referendum whether to stay or leave.
By Nicole Gray • March 23, 2016 -
Why ViiV Healthcare leads the pharma industry in corporate reputation
The HIV company has come in first the past three years in a global survey asking the views of more than 1,000 patient groups.
By Nicole Gray • March 22, 2016 -
Former Turing exec to Senate panel: We warned Shkreli about Daraprim price hike
Turing's former general counsel testified the price increase was "not justified" by any R&D expenditure.
By Nicole Gray • March 18, 2016 -
Despite promising clinical results, uptake challenges continue for Novartis' Entresto
Sales of the heart failure med have disappointed since its launch in July 2015.
By Nicole Gray • March 17, 2016 -
Valeant acquires Orexigen's obesity drug, stock continues its slide
The company announced the acquisition of European rights to Mysimba the same day it revealed significantly downgraded sales forecasts.
By Nicole Gray • March 16, 2016
Previous
